Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
385.00    -7.50 (-1.91%)
Bid:
380.00
Ask:
390.00
Spread: 10.00 (2.632%)
Market Cap: £184.79m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Result of Clinical Study

12 Jun 2012 07:00

RNS Number : 1302F
Tristel PLC
12 June 2012
 



 

TRISTEL plc

Results of Clinical Study

 

Tristel plc ("Tristel"), the manufacturer of infection prevention, contamination control and hygiene products, announces that the results of an "Evaluation of disinfection of flexible nasendoscopes using Tristel wipes: a prospective single blind study", have been published in the Annals of the Royal College of Surgeons of England (Ann R Coll Surg Engi 2012: 94: 185-188).

 

The study, undertaken by the otorhinolaryngology (Ear Nose and Throat or ENT) department at Northwick Park Hospital, North West London, showed the "in-use" efficacy of Tristel wipes in cleaning nasendoscopes of bacteria, fungi and mycobacteria to be 100%.

 

The Tristel wipes system is a unique, patented decontamination method for small flexible endoscopes and ultrasound probes. It comprises a pre-clean wipe to remove surface soiling, a sporicidal wipe that kills harmful organisms within 30 seconds, and a rinse wipe.

 

Tristel CEO, Paul Swinney, commented: "The Northwick Park Hospital study adds to the body of scientific evidence demonstrating the superiority of the wipes system over other, longer established methods. The wipes system for ENT is becoming established as the universal "gold standard" for nasendoscope decontamination in countries where it has been approved for use. These include the UK, Germany, Italy, Spain, Australia and Hong Kong. We anticipate that the wipes system will be approved by the Chinese authorities later this year."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Fiona Henson

Mob: 07886 335 992 or fiona.henson@walbrookpr.com

Paul Cornelius

Mob: 07827 879 460 or paul.cornelius@walbrookir.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEFLFFLQFXBBE
Date   Source Headline
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20224:45 pmRNSInterim dividend confirmation
22nd Feb 202211:30 amRNSDirector/PDMR Shareholding
21st Feb 20224:40 pmRNSSecond Price Monitoring Extn
21st Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSHalf-year Report
17th Feb 20223:00 pmRNSIssue of Equity
1st Feb 20227:00 amRNSConfirmation of Interim Results
13th Dec 20215:13 pmRNSResult of AGM
13th Dec 20217:00 amRNSAGM Statement and notice of results
27th Oct 20217:00 amRNSDirector/PDMR Shareholding
21st Oct 20214:39 pmRNSDirector/PDMR Shareholding
19th Oct 20215:35 pmRNSHolding(s) in Company
18th Oct 20213:50 pmRNSIssue of Equity
18th Oct 202111:59 amRNSDirector/PDMR Shareholding
18th Oct 20217:00 amRNSFinal Results
12th Oct 20215:58 pmRNSHolding(s) in Company
22nd Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSIssue of Equity
10th Aug 20217:00 amRNSIssue of Equity
29th Jul 20216:29 pmRNSTR1: Notification of Major Holdings
21st Jul 20217:00 amRNSTrading update
9th Jul 20211:21 pmRNSIssue of Equity
24th Jun 20217:00 amRNSRegulatory approval for EPA, Canada & South Korea
8th Jun 20217:00 amRNSIssue of Equity
13th May 20213:30 pmRNSIssue of Equity
26th Apr 20213:15 pmRNSDirector/PDMR Shareholding
26th Apr 20212:06 pmRNSSecond Price Monitoring Extn
26th Apr 20212:00 pmRNSPrice Monitoring Extension
26th Apr 202111:05 amRNSSecond Price Monitoring Extn
26th Apr 202111:00 amRNSPrice Monitoring Extension
26th Apr 20217:00 amRNSTrading Update
21st Apr 20213:00 pmRNSIssue of Equity
19th Apr 20211:00 pmRNSIssue of Equity
6th Apr 20211:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
26th Mar 202110:40 amRNSIssue of Equity
4th Mar 20217:00 amRNSDirector/PDMR Shareholding
1st Mar 20215:00 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Feb 20217:00 amRNSHalf-year Report
18th Feb 202111:15 amRNSNotice of investor presentation
15th Feb 202111:00 amRNSIssue of Equity
29th Jan 20217:00 amRNSIssue of Equity
14th Jan 20212:00 pmRNSExercise of Options
24th Dec 20207:00 amRNSDirector Appointment
15th Dec 202011:39 amRNSResult of AGM
15th Dec 20207:00 amRNSAGM Statement and notice of results
2nd Dec 20202:00 pmRNSUpdate to Executive Performance Share Plan 2021
2nd Dec 202010:30 amRNSTristel wins AIM Growth Business of the Year Award
9th Nov 20209:49 amRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.